MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

By sjmartinez • October 11, 2023

Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA, Heering KY, Huang RR, Low JY, Matulionis N, Navone NM, Ye H, Zoubeidi A, Christofk HR, Rettig MB, Reiter RE, Haffner MC, Boutros PC, Shirihai OS, Divakaruni AS, Goldstein AS. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep. 2023 Oct 9;42(10):113221. doi: 10.1016/j.celrep.2023.113221. Epub ahead of print. PMID: 37815914.

Tags: Cancer, CP, Endocrinology, Metabolism, Publications

Related Posts

Advancing biological understanding of cellular senescence with computational multiomics

Li S, Agudelo Garcia PA, Aliferis C, Becich MJ, Calyeca J, Cosgrove BD, Elisseeff J, Farzad N, Fertig EJ, Glass C, Gu L, Hu Q,[...]

Machine Learning to Diagnose Complications of Diabetes

Scheideman AF, Shao MM, Zelada H, Cuadros J, Foreman J, Sarder P, Ho C, Ejskjaer N, Fleischer J, Cichosz SL, Armstrong DG, Mathioudakis N, Wang[...]

Cardiac sodium-glucose co-transporter 1 (SGLT1) contributes to heart failure in a mouse model of diabetic cardiomyopathy

Li Z, Freiberg S, Music ML, Gu L, Nacos S, Phillips JP, Hassan A, Shibbani K, Munir SS, Kumar VK, Halligan L, Michel ME, London[...]